To determine whether the condition of the patient was the result of a primary CMV infection or the reactivation of CMV, we measured CMV IgM and CMV IgG using the leftover serum samples collected on the day of the first admission (10th day of the COVID-19 onset) and found that both CMV IgM and CMV IgG were negative with the following antibody titers: CMV IgM, 0.35 S/CO and CMV IgG, < 6.0 AU/mL (Table 1). This evidence concerns the gene CD40LG and COVID-19.